Ontology highlight
ABSTRACT:
SUBMITTER: Gulley JL
PROVIDER: S-EPMC4839373 | biostudies-literature | 2016 Apr
REPOSITORIES: biostudies-literature
Gulley James L JL Mulders Peter P Albers Peter P Banchereau Jacques J Bolla Michel M Pantel Klaus K Powles Thomas T
Oncoimmunology 20151210 4
Sipuleucel-T is an autologous cellular immunotherapy approved in the US for patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). This significant advance for mCRPC treatment provides healthcare professionals with another effective therapy to extend survival. As an immunotherapy, sipuleucel-T possesses specific characteristics differentiating it from traditional therapies. At a roundtable meeting of experts, sipuleucel-T data were discussed, ...[more]